Hutchmed confident of full year guidance for oncology and immunology

(Alliance News) - Hutchmed (China) Limited on Wednesday said it remains on track to meet full ...

Alliance News 31 July, 2024 | 1:41PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Hutchmed (China) Limited on Wednesday said it remains on track to meet full year guidance for its oncology/immunology business, despite a fall in revenue.

Hutchmed is a Hong Kong-based biopharmaceutical company focused on the development and commercialisation of therapies and immunotherapies for the treatment of cancer and immunological diseases.

Hutchmed reported a 43% fall in revenue to USD305.7 million for the six months that ended June 30 from USD532.9 million a year before.

Within this, oncology/immunology consolidated revenue was USD168.7 million for the half, down from USD359.2 million a year prior. However, first-half oncology/immunology product revenue rose 59% to USD127.8 million from USD80.1 million year-on-year, while R&D revenue within the consolidated total was USD40.8 million, down from USD279.0 million.

Net income decreased by 85% to USD26.2 million for the half from USD169.5 million a year before.

Looking forward, Hutchmed said it remains on track to meet its full-year guidance for oncology/immunology.

Thanks to the rising product revenue, consolidated revenue for oncology/immunology is expected to be between USD300 million to USD400 million, with a 30% to 50% growth rate.

Chair Dan Eldar commented: "Hutchmed has delivered strong performance in the first half of this year. The team has made significant progress implementing our strategy in discovering and developing novel, effective medicines; conducting clinical trials in our home market and in the global markets; and rapidly advancing regulatory and commercial goals."

Hutchmed shares were up 5.0% to 296.00 pence each in London on Wednesday afternoon.

By Lydia Doye, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
HUTCHMED (China) Ltd 300.00 GBX 6.38 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures